绝经后乳腺癌幸存者内分泌治疗与心血管风险
研究基于英国初级保健与医院数据(2002-2016)及美国SEER-Medicare数据(2008-2013)两项前瞻性队列,比较绝经后乳腺癌幸存者中芳香化酶抑制剂(AI)与他莫昔芬使用者的12种临床相关心血管结局风险。结果显示AI使用者冠心病风险高于他莫昔芬使用者,但与美国未接受内分泌治疗者相比,两种药物均未显示更高风险,他莫昔芬使用者风险更低;AI相对他莫昔芬的较高风险可能源于他莫昔芬的保护效应而非AI的心脏毒性。
要点
- AI使用者冠心病风险高于他莫昔芬使用者(英国HR 1.29,95%CI 0.94-1.76;美国HR 1.29,95%CI 1.06-1.55)。
- 与美国未接受内分泌治疗者相比,他莫昔芬使用者冠心病风险更低(HR 0.74,95%CI 0.60-0.92),AI使用者无显著差异。
- 他莫昔芬使用者静脉血栓栓塞风险高于AI使用者及未暴露者。
核心结论
- AI相对于他莫昔芬的较高心血管风险可能由他莫昔芬的保护效应驱动,而非AI的心脏毒性效应。
研究设计与样本
- 采用Cox调整比例风险模型比较AI与他莫昔芬使用者的心血管风险,并在美国数据中比较两类药物使用者与未接受内分泌治疗者的风险。
主要发现
- 两国AI使用者冠心病风险均高于他莫昔芬使用者:英国年龄标化发病率10.17 vs 7.51/1000人年,HR 1.29(95%CI 0.94-1.76);美国36.82 vs 26.02/1000人年,HR 1.29(95%CI 1.06-1.55)。
- 美国数据中,与他莫昔芬相比未暴露者冠心病风险更高(年龄标化发病率26.02 vs 35.19/1000人年,HR 0.74,95%CI 0.60-0.92),AI与未暴露者无显著差异(36.82 vs 35.19,HR 0.96,95%CI 0.83-1.10)。
- 心律失常、心力衰竭和瓣膜性心脏病呈现相似模式。
- 他莫昔芬使用者静脉血栓栓塞风险高于AI使用者及未暴露者。
临床怎么用
- 对绝经后乳腺癌幸存者选择内分泌治疗时,应综合评估心血管风险与静脉血栓栓塞风险,个体化权衡AI与他莫昔芬的获益与风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Examine the effect of tamoxifen and aromatase inhibitors (AIs) on the risk of 12 clinically relevant cardiovascular outcomes in postmenopausal female breast cancer survivors. METHODS: We carried out two prospective cohort studies among postmenopausal women with breast cancer in UK primary care and hospital data (2002-2016) and US Surveillance, Epidemiology and End Results-Medicare data (2008-2013). Using Cox adjusted proportional hazards models, we compared cardiovascular risks between AI and tamoxifen users; and in the USA, between users of both drug classes and women receiving no endocrine therapy. RESULTS: 10 005 (UK) and 22 027 (USA) women with postmenopausal breast cancer were included. In both countries, there were higher coronary artery disease risks in AI compared with tamoxifen users (UK age-standardised incidence rate: 10.17 vs 7.51 per 1000 person-years, HR: 1.29, 95% CI 0.94 to 1.76; US age-standardised incidence rate: 36.82 vs 26.02 per 1000 person-years, HR: 1.29, 95% C I1.06 to 1.55). However, comparisons with those receiving no endocrine therapy (US data) showed no higher risk for either drug class and a lower risk in tamoxifen users (age-standardised incidence rate tamoxifen vs unexposed: 26.02 vs 35.19 per 1000 person-years, HR: 0.74, 95% 0.60 to 0.92; age-standardised incidence rate AI vs unexposed: 36.82 vs 35.19, HR: 0.96, 95% CI 0.83 to 1.10). Similar patterns were seen for other cardiovascular outcomes (arrhythmia, heart failure and valvular heart disease). As expected, there was more venous thromboembolism in tamoxifen compared with both AI users and those unexposed. CONCLUSIONS: Higher risks of several cardiovascular outcomes among AI compared with tamoxifen users appeared to be driven by protective effects of tamoxifen, rather than cardiotoxic effects of AIs.
引用
- Matthews AA, Peacock Hinton S, Stanway S, et al. Endocrine therapy use and cardiovascular risk in postmenopausal breast cancer survivors. Heart. 2020. PMID: 33177117. doi:10.1136/heartjnl-2020-317510
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。